ReviewDrug metabolism and pharmacokinetics2026
Role of metabolites in drug-drug interactions.
Review in Drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Personalized Medicine, Storied Past, Contentious Present, Promising Future.Journal of personalized medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Since the publication of the metabolites in safety testing (MIST) guidance by the US FDA in 2009, there has been continuous interest and expansion in research aimed at predicting and characterizing circulating metabolites. Several systematic reviews and original research articles have been published to assess the role of metabolites in drug-drug interactions. Abundant circulating metabolites have been found to be common with classic cytochrome P450 (CYP) enzyme inhibitors and with new drugs in development. This has raised the need for better tools to predict significant circulating metabolites from preclinical data to streamline metabolite testing. This review summarizes the current recommendations for metabolite testing, evaluates the existing data on reversible and time-dependent inhibition of CYP enzymes by circulating metabolites, and explores the potential inhibition of drug transporters by circulating metabolites. The possible role of metabolites in induction of CYP enzymes is also discussed. The mathematical methods to incorporate multiple precipitants into risk assessment and quantitative prediction methods for inhibition and induction are summarized. Finally, the unique considerations regarding PBPK modeling of metabolites are discussed to highlight potential differences in the metabolite liver concentrations used in static versus more dynamic PBPK prediction methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.